✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Valbenazine tosylateis the generic ingredient in one branded drug marketed by Neurocrine and is included in one NDA. There are twenty patents protecting this compound. Additional information is available in the individual branded drug profile pages.
Valbenazine tosylate has one hundred and seventy-nine patent family members in thirty-two countries.
One supplier is listed for this compound. There are two tentative approvals for this compound.
Summary for valbenazine tosylate
|Finished Product Suppliers / Packagers:||1|
|Raw Ingredient (Bulk) Api Vendors:||11|
|Patent Litigation and PTAB cases:||See patent lawsuits and PTAB cases for valbenazine tosylate|
|DailyMed Link:||valbenazine tosylate at DailyMed|
Generic filers with tentative approvals for VALBENAZINE TOSYLATE
The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.
Pharmacology for valbenazine tosylate
|Drug Class||Vesicular Monoamine Transporter 2 Inhibitor |
|Mechanism of Action|| Vesicular Monoamine Transporter 2 Inhibitors |
|Country||Patent Number||Title||Estimated Expiration|
|China||111655034||施用某些VMAT2抑制剂的方法 (METHODS FOR ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS)||See Plans and Pricing|
|Morocco||43116||DITOSYLATE DE VALBÉNAZINE ET POLYMORPHES ASSOCIÉS||See Plans and Pricing|
|Brazil||112021000019||métodos para administração de certos inibidores de vmat2||See Plans and Pricing|
|Mexico||2020003421||METODOS PARA LA ADMINISTRACION DE CIERTOS INHIBIDORES DEL TRANSPORTADOR VESICULAR DE MONOAMINA 2 (VMAT2). (METHODS FOR THE ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS.)||See Plans and Pricing|
|Japan||2021502959||特定のＶＭＡＴ２インヒビターを投与するための方法||See Plans and Pricing|
|Japan||2021528481||特定のＶＭＡＴ２阻害剤を投与するための方法||See Plans and Pricing|
|Morocco||44127||PROCÉDÉS DE SYNTHÈSE POUR LA PRÉPARATION DE DI(4-MÉTHYLBENZÈNESULFONATE) DE 2-AMINO-3-MÉTHYLBUTANOATE DE (S)-(2R,3R,11BR)-3-ISOBUTYL-9,10-DIMÉTHOXY-2,3,4,6,7,11B-HEXAHYDRO-1H-PYRIDO[2,1,-A]ISOQUINOLÉIN-2-YL||See Plans and Pricing|
|>Country||>Patent Number||>Title||>Estimated Expiration|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.